Results for this period
Full year1 September 2025–31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The core market benefited from winning new large-scale projects and replacement demand for the new Miffy product lineup. In overseas markets, projects in Taiwan that had shifted between periods and sales from the Seoul branch increased. Patient wear, however, saw lower revenue due to the reactionary decline following a large project in the previous fiscal year and customers holding back on purchases to replenish inventories. On the earnings side, the company worked to address rising costs through price revisions, shifting production overseas and expanding the use of overseas materials.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 September 2025–31 August 2026 |
| Net Sales | ¥17,205 million (YoY +1.3%) |
| Operating profit | ¥3,625 million (YoY +1.2%) |
| Ordinary income | ¥3,835 million (YoY +3.5%) |
| Profit attributable to owners of the parent | ¥2,650 million (YoY +3.0%) |
| Net income per share | ¥88.21 |
| Operating Margin | 21.1% |
| Equity ratio | End of the current fiscal period 92.6% / End of previous period 92.5% |
| Total assets | ¥42,192 million |
| Net assets | ¥39,056 million |
| Cash flows from operating activities | ¥3,528 million |
| Cash flows from investing activities | ¥1,670 million |
| Cash flows from financing activities | ¥-5,050 million |
| Cash and cash equivalents at end of period | ¥4,899 million |
| Full-year earnings forecast | Net Sales ¥17,500 million (YoY +1.7%) / Operating profit ¥3,602 million (YoY -0.7%) / Ordinary income ¥3,893 million (YoY +1.5%) / Net income ¥2,660 million (YoY +0.4%) |
| Annual Dividend Forecast | ¥100 → ¥70（-30.0%） |
| Payout ratio | 79.4% |
| Shareholder Return Policy | The policy is to maintain a dividend payout ratio of at least 50% based on the Company's standalone net income. |
| Depreciation and amortization | ¥297,846 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥10,436 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥3,486 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | At a meeting of the Board of Directors held on 1 October 2026, the Company resolved to acquire up to 600,000 shares of treasury stock through market purchases from 2 October to 31 December 2026, with a total acquisition price capped at ¥1 billion. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Securities analysts |
| Issued Shares at Period-End | 30,736,000 shares |
| Treasury Shares at Period-End | 1,331,526 shares |
| Factors Behind Changes in Business Performance | The core market benefited from winning new large-scale projects and replacement demand for the new Miffy product lineup. In overseas markets, projects in Taiwan that had shifted between periods and sales from the Seoul branch increased. Patient wear, however, saw lower revenue due to the reactionary decline following a large project in the previous fiscal year and customers holding back on purchases to replenish inventories. On the earnings side, the company worked to address rising costs through price revisions, shifting production overseas and expanding the use of overseas materials. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue benefited from winning new large-scale projects, replacement demand for the new Miffy product lineup, deliveries for projects in Taiwan that had shifted between periods, and sales from the newly established Seoul branch. Patient wear, however, saw lower revenue due to the reactionary decline following a large project in the previous fiscal year and customers holding back on purchases to replenish inventories. On the earnings side, the company worked to address rising costs for raw materials, labor and imported materials by advancing price revisions, shifting production overseas and expanding the use of overseas materials.